You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK)自研產品童顏水凝嘉樂妍®獲批醫療器械生產許可
格隆匯 09-30 07:08

格隆匯9月30日丨四環醫藥(00460.HK)發佈公吿,由集團自主研發生產的童顏水凝(商品名:嘉樂®)(2毫升╱支)於2021年9月正式獲得國家藥品監督管理局批准的醫療器械生產許可。

嘉樂妍®為集團自主研發的水溶性凝膠產品。該產品於2021年8月11日獲得國家藥監局的註冊批准,並於2021年9月16日獲得醫療器械生產許可。嘉樂妍®呈類白色液體混懸液,液體混懸均勻,以無菌預灌封注射器形式交付,確保產品安全性。可用於表面或創面,對皮膚起到屏障作用,對創面部位可促進膠原蛋白和組織細胞再生。

左旋聚乳酸屬α-羥基酸家族,具有良好的生物吸收性和生物相容性的可生物降解材料,可被人體自然代謝,基本不會產生不良反應,且左旋乳酸可促進局部皮膚的新陳代謝,改善皮膚質量。隨着集團第一款自主研發的醫療美容產品的獲批及上市,將進一步補充集團在醫美領域的產品管線,完善集團醫美產品矩陣的打造。這將有助於集團加快拓展醫美自研產品管線,提高集團綜合實力,大幅增強集團在醫美領域的核心競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account